
Biodesix adds lung imaging test to pipeline with 2028 launch target
The Vanderbilt development partnership will pair CT imaging with blood biomarkers, with initial performance data due Dec. 3.

An unnamed customer is due to deploy 3 MW on Nov. 1, with initial monthly bills split between US$750,000 in service fees and power charges.

The Vanderbilt development partnership will pair CT imaging with blood biomarkers, with initial performance data due Dec. 3.

Selected Calandrias feed lifted mill production as Cerrado targeted the upper end of its unchanged annual guidance range.
The financially settled COMEX contract would track a Fastmarkets APT assessment for Rotterdam and Baltimore.
Half of induction responders were in remission at one year in the uncontrolled Phase 3 study; Lilly plans global regulatory submissions.

The electrolyser maker ended April with £215.6 million in cash, supported by a £40 million equity investment from Great British Energy.

The four businesses generated 36.57 per cent of first-half net profit before intercompany eliminations, and consideration would arrive in instalments.

The first stage requires US$1.25 million in spending and payments over six months to lift its interest to 30 per cent.

The miner kept annual production guidance unchanged as Sierra Gorda paid a US$153 million distribution to South32.
The uncontrolled Phase 2 analysis used a September 2025 cutoff; Zentalis will present the survival data at ESMO on Oct. 23.
Pure holdings remained at zero in the Oct. 16 snapshot, but the weekly post disclosed neither sale prices nor dollar proceeds.
An Oct. 15 filing puts the appointment's effective date at Oct. 14 and details cash and equity terms for the new finance chief.
The Oct. 15 petition asks to participate in the PUC case over transmission costs and interruptible service for large data centres.
Three configurations include a single-seat Rocket version, while Porsche's vision model previews a permanent platform above the 911.
Mapping and sampling will cover 17 Golden Scheelite claims; the company disclosed no program budget or assay-reporting date.
The automaker will contribute RMB1 billion, while outside investors commit RMB625 million to MHX Technology under conditional subscription agreements.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The mine produced 39 ounces in September and forecasts about 500 ounces in December as equipment and processing changes take effect.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The once-daily device adds a second ZILBRYSQ self-injection format for adults with anti-AChR-positive gMG, with availability expected in the first quarter of 2027.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The AI infrastructure developer says financing and an investment disposal supported its cash increase as first-half revenue fell sharply.
Loughton was due to host about 23,000 chips from early 2027, while Nscale is pursuing an IPO after announcing convertible financing.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Langer Heinrich produced 1.00 million pounds in the September quarter, while unit production costs rose to US$61.6 a pound.

The proposed project debt awaits lender diligence and final documents as Phase 1 completion remains targeted for December 2026.

Myriad would issue 1,571,268 shares, while Green Shift would retain a 2 per cent royalty with a partial buyback right.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Cash earnouts tied to 2026 and 2027 earnings add to the base price for a grower supplying nearly all 69 shops in the Dutch pilot.

The Oct. 15 move leaves Curaleaf's national store count at 189, with a York grand opening celebration scheduled for Oct. 23.

Three brands will be dropped as global teams take over operations, with full annualized savings forecast for fiscal 2028.

The approval adds adults with high-grade, BCG-unresponsive disease ahead of the Jan. 6, 2027 review target.